Uus-Meremaa - inglise - Medsafe (Medicines Safety Authority)

viatris limited - pimecrolimus 10 mg/g;   - topical cream - 1 % - active: pimecrolimus 10 mg/g   excipient: benzyl alcohol cetyl alcohol citric acid glyceryl monostearate medium-chain triglycerides oleyl alcohol propylene glycol purified water sodium cetostearyl sulfate sodium hydroxide stearyl alcohol - patients 3 months of age and older with atopic dermatitis (eczema) for the: · short-term treatment of signs and symptoms; and · intermittent long-term treatment of emerging and resolving lesions in atopic dermatitis where topical corticosteroids are ineffective, intolerable or inappropriate.

Malaisia - inglise - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pfizer (malaysia) sdn. bhd. - oestrogens,conjugated -

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

bayer plc - not applicable

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - alpha-1-proteinase inhibitor, quantity: 4000 mg - liquid, multipurpose - excipient ingredients: monobasic sodium phosphate monohydrate; alanine; water for injections - prolastin? c liquid is an alpha-1-proteinase inhibitor indicated to increase serum alpha-1-proteinase inhibitor levels in adults with congenital deficiency of alpha-1- antitrypsin and with clinically significant emphysema (fev1 <80%).,the data for clinical efficacy of prolastin? c liquid is derived from changes in the biomarkers alpha-1 anti-protease level and ct lung density. efficacy on fev1 or patient relevant endpoints such as quality of life or pulmonary exacerbations has not been established in randomised clinical trials.,clinical trials have only included patients who were not smoking.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - alpha-1-proteinase inhibitor, quantity: 500 mg - liquid, multipurpose - excipient ingredients: monobasic sodium phosphate monohydrate; alanine; water for injections - prolastin? c liquid is an alpha-1-proteinase inhibitor indicated to increase serum alpha-1-proteinase inhibitor levels in adults with congenital deficiency of alpha-1- antitrypsin and with clinically significant emphysema (fev1 <80%).,the data for clinical efficacy of prolastin? c liquid is derived from changes in the biomarkers alpha-1 anti-protease level and ct lung density. efficacy on fev1 or patient relevant endpoints such as quality of life or pulmonary exacerbations has not been established in randomised clinical trials.,clinical trials have only included patients who were not smoking.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme australia pty ltd - oestriol -

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

evergrowth pty ltd - propolis resin, quantity: 200 mg/ml (equivalent: lead, qty 2 microgram/ml; equivalent: propolis, qty 300 mg/ml) - liquid, multipurpose - excipient ingredients: propylene glycol - antioxidant/reduce free radicals formed in the body ; maintain/support general health and wellbeing ; decrease/reduce/relieve symptoms of mild mouth ulcers ; traditionally used in chinese medicine to decrease/reduce/relieve mild throat inflammation ; traditionally used in western herbal medicine to decrease/reduce/relieve mild throat inflammation ; decrease/reduce/relieve mild throat inflammation ; traditionally used in chinese medicine to decrease/reduce/relieve symptoms of mild throat infection ; traditionally used in western herbal medicine to decrease/reduce/relieve symptoms of mild throat infection ; decrease/reduce/relieve throat mucous membrane irritation/inflammation ; helps decrease/reduce/relieve symptoms of minor skin wounds (cuts, scratches and abrasions) ; traditionally used in western herbal medicine to maintain/support wound healing ; traditionally used in chinese medicine to maintain/support wound healing

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - aripiprazole, quantity: 20 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; maize starch; hyprolose; croscarmellose sodium; magnesium stearate - tevaripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - estradiol valerate, quantity: 1 mg - tablet, sugar coated - excipient ingredients: iron oxide yellow; glycerol; povidone; macrogol 6000; magnesium stearate; calcium carbonate; sucrose; titanium dioxide; glycol montanate; maize starch; purified talc; lactose monohydrate - indications as at 19 july 2004: short term treatment of climacteric complaints after the cessation of monthly bleeding, or deficiency symptoms after oophorectomy or radiological castration for non-carcinomatous diseases, such as hot flushes, outbreaks of sweat, sleep disturbances, depressive moods, irritability, headaches, dizziness. progynova has also a favourable influence on bladder irritation (a not infrequent occurrence in the climacteric), signs of cutaneous and mucosal involution (particularly in the genital region) which normally occur with advancing age.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

wyeth pharmaceuticals llc, a subsidiary of pfizer inc. - estrogens, conjugated (unii: iu5qr144qx) (estrogens, conjugated - unii:iu5qr144qx) - estrogens, conjugated 0.625 mg in 1 g -             premarin vaginal cream therapy should not be used in women with any of the following conditions: premarin vaginal cream should not be used during pregnancy [see contraindications (4)] . there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy. premarin vaginal cream should not be used during lactation. estrogen administration to nursing women has been shown to decrease the quantity and quality of the breast milk. detectable amounts of estrogens have been identified in the breast milk of women receiving estrogen therapy. caution should be exercised when premarin vaginal cream is administered to a nursing woman. premarin vaginal cream is not indicated in children. clinical studies have not been conducted in the pediatric population. there have not been sufficient numbers of geriatric women involved in clinical studies utilizing premarin vaginal cream to determine whether those over 65 years of age differ from younger subjects in their response to premarin vaginal cream. the women's health initiative studies in the whi estrogen-alone substudy (daily ce [0.625 mg]-alone versus placebo), there was a higher relative risk of stroke in women greater than 65 years of age [see warnings and precautions (5.2), and clinical studies (14.2)] . in the whi estrogen plus progestin substudy (daily ce [0.625 mg] plus mpa [2.5 mg] versus placebo), there was a higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age [see warnings and precautions (5.2, 5.3), and clinical studies (14.2)] . the women's health initiative memory study in the whims ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable dementia in women receiving estrogen-alone or estrogen plus progestin when compared to placebo [see warnings and precautions (5.4), and clinical studies (14.3)] . since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women8 [see warnings and precautions (5.4), and clinical studies (14.3)] . the effect of renal impairment on the pharmacokinetics of premarin vaginal cream has not been studied. the effect of hepatic impairment on the pharmacokinetics of premarin vaginal cream has not been studied.